Douglas Boneparth, Bone Fide Wealth President, joined Yahoo Finance's Jen Rogers, Myles Udland, Dan Roberts, and Melody Hahm to discuss the best approach to retirement planning during the coronavirus pandemic.

It’s no secret, a large number of high-profile companies have taken a serious beating since the pandemic’s onset. Possibly none more well-known than Disney (DIS). COVID-19 has necessitated theme park closures, a halt of live film production, and a delayed movie release schedule – all resulting in last week’s crushing F2Q20 report.Yet, Northland analyst Bernie McTernan argues that there are several reasons to remain positive on the House of Mouse.Glimmers of hope were provided during the earnings call, as Disney announced it will reopen its Shanghai theme park next week on May 11. McTernan assumes that domestically, Disney’s parks will open in September. Nevertheless, the forced enclosures are set to impact the balance sheet for a while, and McTernan forecasts it will take “at least two years for Disney to generate the revenue/segment operating income they could have in FY'20.”Disney has also taken emergency measures to preserve cash flow through the pandemic. The company has suspended the dividend, reduced capex and furloughed employees. Although drastic, in an environment which is likely resulting in negative FCF, McTernan believes the measures should “provide a margin of safety.”“Importantly,” McTernan added, “We believe these levers can be switched back on when the operating environment begins to normalize.”But there is another recent positive development for investors to consider. When Disney announced in April that the launch of its new streaming service Disney+ had exceeded expectations and already boasted 50 million global subscribers, the numbers took the Street by surprise. McTernan believes there’s more to come.“We estimate Disney+ will reach 65M global subscribers by the end of September '20E and attain profitability in FY'23E, a year earlier than originally guided… As cord cutting grows, Disney+ is the reason to own the stock,” McTernan opined.To this end, McTernan keeps a Buy rating on Disney, along with a $130 price target, which implies nearly 20% upside from current levels. (To watch McTernan’s track record, click here)And what abut the rest of the Street? Based on 11 Buy ratings, 10 Holds and 1 Sell, Disney has a Moderate Buy consensus rating. With an average price target of $120.35, the analysts expect upside of nearly 12% over the coming months. (See Disney stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * RBC: 2 Strong Value Stocks to Buy Now * Look Beyond 2Q, General Motors Will Outperform the Sector, Says Analyst * Investor James Richman Bets GE Stock Is Set to Experience Almost 100% Rally  * Coronavirus Vaccine Could Add Massive Value to This Small-Cap Stock, Says Analyst

As of Thursday evening, more than 40 percent of the funds remained available in the Paycheck Protection Progam

Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors will be delighted, with the company turning in some strong numbers...

The latest data analyzed by The Block Research shows that bitcoin miners made 8% more revenue in April as compared to March, thanks to a gradual recovery in bitcoin’s price.The post Bitcoin miners made $412.5 million in revenue during April, new data indicates appeared first on The Block.

The analysts might have been a bit too bullish on Consolidated Edison, Inc. (NYSE:ED), given that the company fell...

Roku posted a strong first-quarter earning report after the bell on Thursday. Yahoo Finance’s On The Move panel share the details.

Could we see the yellow metal at $5,000 or even higher amid the coronavirus crisis? We invite you thus to read our today’s article and find out how high gold prices can go in this downturn.

Above: A Hydrogen Powered Truck from Nikola Corporation, Which Is Merging with VectoIQ Acquisition Corp. By John Jannarone Since the coronavirus crisis drove the market to multiyear lows, the flow of initial public offerings has ground to a veritable halt. That is, except, for special purpose acquisition companies, or SPACs. Some $2.7 billion has been […]

When tickets for the May 11 reopening of Shanghai Disneyland went on sale, they sold out within minutes. Park officials said they are taking "a deliberate approach”, such as requiring physical distancing and sharply reducing capacity. Jen Rogers, Myles Udland and Akiko Fujita discuss what the reopening of the first major theme park says about consumer demand post-coronavirus.

Bitcoin is growing against the entire crypto market, adding 3% in the last 24 hours. The first cryptocurrency is not only above $9K but is close to reaching $10K.

The move will help Southwest save cash at a time when U.S. airlines collectively burn more than $10 billion a month. Last month, rival United Airlines agreed to sell and lease back 22 planes to aircraft investor Bank of China Aviation. United, however, did not specify the size of the deal.

The market 'has been driven by sentiment recently' — and is overvalued, warns one veteran strategist.

Each decade has an investment theme that favors one asset class over another. What performed well over the last decade generally underperforms during the next.

Director of Fiscal Policy at the American Action Forum Gordon Gray joins Yahoo Finance’s Seana Smith to break down the April jobs report and how some workers are making more on unemployment compared to their wages before the coronavirus pandemic.

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing. An analyst at BofA Securities said Friday that now is the time to go from defensive to offensive in the sector, as quarantines are winding down in several parts of the globe.The Biopharma Analyst Analyst Geoff Meacham shortlisted Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Bristol-Myers Squibb Co (NYSE: BMY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Amgen, Inc. (NASDAQ: AMGN) as biopharma stocks where he would put his money to work.The analyst has the following ratings and price targets for the shares: * Lilly: Buy/$165 * Vertex: Buy/$300 * Bristol-Myers Squibb: Buy/raised the price target from $75 to $80 * BioMarin: Buy/lifted price target from $110 to $120 * Amgen: Buy/price target increased from $265 to $2755 Reasons For BofA's Bullish Disposition BofA is increasingly bullish on the biopharma group due to the following factors, Meacham said: * Expectations for robust revenue growth of 6% in the second half of 2020 compared to the first-half, which is double that of the S&P 500's revenue growth. * Reasonable price-earnings for the stocks in the sector. * Many value-creating events lined up for the second half. * Lower policy risk stemming from goodwill earned from the COVID-19 pipeline. * A consistently positive FDA backdrop.Q1 Earnings Get 'A' Grade All of the big biotechs and major pharma companies reported both revenue and adjusted EPS beats in the first quarter, with Lilly and Vertex even raising some parts of their 2020 guidance, Meacham said.Citing slower new starts and forex headwinds, Bristol-Myers Squibb and BioMarin lowered their 2020 revenue guidance, but maintained their EPS guidance, the analyst said. Meacham expressed surprise at Merck & Co., Inc. (NYSE: MRK) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) lowering their 2020 revenue and adjusted EPS guidance, given his belief that oncology or orphan diseases wouldn't be as sensitive to COVID-19 disruption.See also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Lilly One of The Higher Quality Stocks In BofA's Coverage Lilly is a source of differentiated growth given its early product cycle and diversified base business, including diabetes, immunology and immunotoxicology and migraine, and an advancing late-stage pipeline of potentially best-in-class or first-in-class therapies, Meacham said.The analyst said he likes Lily's potential for additional earnings growth in 2020-2021 and views Lilly as one of the higher quality stocks in his coverage despite its higher valuation. The prospects for 2021 look attractive, with selpercatinib potentially launching in non-small cell lung cancer and thyroid cancer by year's end, and tirzepatide approval in 2021 representing a "step change" for the diabetes franchise, he said. Consensus For Vertex To Move Higher? Vertex has a richer -- though well-deserved -- valuation, due to its differentiated growth profile, Meacham said.Given that Vertex's commercial execution is largely unaffected by the COVID-19 pandemic, the analyst said investors will begin to look forward to 2021 sooner than for other companies with more commercial risk.BofA expects consensus estimates to continue to move higher, making Vertex's valuation even more attractive.Bristol-Myers Has Highly Differentiated Growth With an estimated 8% revenue growth and 19% EPS growth in 2021 compared to 5-6% and 12%, respectively, for peers, and with six new launches expected this year, 2020 is shaping up to be a very robust period for Bristol-Myers despite the ongoing COVID-19 headwinds, Meacham said. The analyst said the company's growth looks highly differentiated.An increasingly diversified product mix and beatable launch expectations position the company for meaningful upside to consolidated P&L, with improving synergies, he said. BioMarin's 'Game-Changing' Late-Stage Pipeline BioMarin's late-stage pipeline in valrox and vosoritide have improved its growth outlook, Meacham said.The analyst termed the company's late-stage pipeline as "game-changing." The second-half launch of Roctavian is the most important catalyst for the company this year, with the product likely to accelerate the company's already above-average growth profile, he said. "We see BioMarin as one of the higher quality names in our coverage universe given its clean growth story and it remains our SMid cap top pick." Amgen Looks To New Product Growth To Compensate For Legacy Product Erosion The long-term outlook for Amgen's Otezla is improving given the recently announced Phase 3 data for mild-to-moderate psoriasis, Meacham said.The company rapidly refocused its story from legacy product erosion to new product growth with the acquisition of Otezla from the Bristol/Celgene deal, the analyst said. "Since then Amgen's growth profile has only improved, led by an expanded addressable market for Otezla, outperforming Amgen Biosimilars and Evenity franchises, aggressive formulary negotiation for Aimovig, and an exciting pipeline in AMG 510 and tezepelumab looking to contribute as soon as 2021." The Price Action The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) was last seen trading up 1.25% to 128.76, adding to its 5.6% year-to-date gain. Related Link: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace See more from Benzinga * The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda * The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500 * The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Retailers that were already ailing before the coronavirus are beginning to crumble as the crisis raises the threat of store closings and bankruptcy.

Moody’s Analytics analyzed U.S. metro areas capabilities for a strong recovery post-coronavirus using two primary factors: population density and educational attainment.

Many U.S. airliners are "reasonably confident" that a return to 30% to 50% of pre-COVID-19 capacity by the end of 2020 is possible, Boeing Co (NYSE: BA) CEO David Calhoun said in a Fox Business interview Friday. A 'Crawl Back' For Airline Industry Investors expecting a swift return to 2019 traffic levels may be disappointed, as the industry will "slowly crawl back" to pre-crisis levels over a three-year period, Calhoun said.It will take another two years afterward for the industry to resume the growth curve seen over the past 20 years, the CEO said. The timeline could change based on different factors, including a quicker-than-expected development of a COVID-19 vaccine that results in a "more robust" recovery, he said.Boeing 737 MAX Update The pandemic is far from Boeing's only problem to deal with, as the two 737 MAX crashes set the company back two years, Calhoun said.The company continued to manufacture new MAX planes, and even if they are grounded today, the planes will ultimately "find their way into the market."Any near-term market share losses will be erased as the MAX undergoes a "catchup" phase, he said.Boeing's talks with the FAA regarding the certification process are "constructive" and "thorough," Calhoun said.The work-from-home and travel restrictions do add by default additional time to any eventual certification for the MAX to return to the skies, the CEO said. Boeing also expects to resume 737 MAX production this month after it was suspended in January, he said. The company has already announced its plans to build fewer planes moving forward to compensate for its existing inventory.Boeing's Bond Deal Boeing already suspended its dividend and will prioritize the payback of its new $25-billion bond issue until "we get back to the same kind of balance sheet" that existed prior to the MAX crashes, he said. After that, the company will plan on how to resume cash distributions to shareholders, Calhoun said -- but not until Boeing "significantly" pays down debt. Boeing shares were trading 3.27% higher at $132.86 at the time of publication Friday.Related Links:Boeing's Large Bond Deal Solves Liquidity Problem, Says Bullish Goldman SachsBoeing Analyst Turns Bullish After Deep Sell-OffSee more from Benzinga * Southwest Airlines CEO On 'Breathtaking' March Declines, Financial Plans * Boeing Shares Lose Altitude On New Coronavirus-Driven Concerns * Carly Fiorina Blasts Corporate Bailout Funding In T Coronavirus Relief Bill(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

What happened to my stimulus money? Many who receive government benefits and others continue to wonder in early May.

Moderna CEO Stephane Bancel stated that the company’s new coronavirus vaccine, which was clear for a phase 2 trial on Thursday by the FDA, would not be ready for immediate release to the public and that the distribution of the potential vaccine would need to be handled carefully between Moderna and the White House. Yahoo Finance’s Anjalee Khemlani joins The Final Round panel to break down the latest news about the coronavirus.

Does history repeat? Many of us, no doubt, remember the crash of the doc.com bubble back in 2000, and at least one analyst sees that pattern repeating before our eyes. Will Meade, who built his reputation in stock analysis with Goldman Sachs, believes that the current rally is only temporary, and that the markets are likely to fall again in 2H20 – by as much as 40%.Meade points that, like in 2000, we have the risk and uncertainty of a Presidential election coming up, and then adds, “The NASDAQ in 2000 did a similar bear market bounce as stocks this year — dropped 40%, then bounced 42% off the bottom retracing 61.8% of its drop. It stalled then fell 43%, making a new low four months later.” If Meade is right, then the true market bottom is due to hit us in late July or early September.The analyst is not all doom and gloom, however. While he is predicting bad news and tough times for the stock markets, he also points out that investors can act now to buffer their personal positions. His advice: move to liquid assets and build a cash savings buffer.Shoring up the savings account is only part of a strong defensive strategy. Investors can also shift their portfolio toward dividend stocks, relying on the steady income from the dividend payments to compensate for lower share price appreciation.We’ve used TipRanks database to find three high-yielding stocks that offer reliable payments – and all three have gotten the thumbs up from Maxim analyst Michael Diana.Ellington Financial, Inc. (EFC)We’ll start in the financial sector, with a small-cap company in the mortgage finance niche. Ellington operates as an investor, putting money into consumer loans, equity investments, mortgage backed securities, and both residential and commercial mortgages. It’s a standard portfolio for a mortgage-focused real estate investment trust.As an REIT, Ellington naturally offers a high dividend. REITs are required to a return a high percentage of profits to investors, and dividends are a sure way to comply with that regulatory provision. In response to the COVID-19 epidemic, and consequent economic damage, Ellington had to reduce its monthly payment starting with the April 29 payout. However, the company is maintaining a 54% payout ratio – returning more than half of earnings to investors. The 8-cent per share payment annualized to 96 cents, and offers investors a yield of 10%.Right now, the Fed’s key interest rate is down to the 0 to 25 basis point range, and Treasury bonds are yielding less than 1%. Even among dividend stocks, the average yield is just 2%. So, EFC’s 10% dividend yield is a fantastic return. Looking ahead, the company is expected to show 40 cents per share in earnings for Q1, more than enough to maintain the new monthly dividend.Maxim’s Michael Diana has tagged EFC as a ‘top pick,’ particularly noting the company’s strong management team: "Managing an mREIT even in 'normal' times is a difficult task, as the manager must balance leverage, prepayment protection, interest income, hedging, and diversity of financing sources to position the investment portfolio to withstand unexpected shocks without giving up too much income. When an unexpected shock does occur, crisis management skills are required to dynamically hedge and reposition the portfolio. We have followed EFC longer than any other analyst and, in our view, EFC management possesses all of these skills."Diana puts an $18 price target on EFC shares, implying a whooping 82% upside potential that fully supports his Buy rating. (To watch Diana’s track record, click here)Wall Street agrees with Diana’s assessment here. The analyst consensus on this stock is a Strong Buy, and it is unanimous, based on 4 Buy reviews set in recent weeks. Shares are selling at a comfortable entry point, just $9.87, and the average price target of $14.38 suggests room for a robust 46% upside growth this year. (See Ellington stock analysis on TipRanks)AGNC Investment (AGNC)Based in the Maryland suburbs of Washington DC, AGNC is another REIT. The company’s portfolio is centered on residential mortgage-backed securities, but with a twist. Most of AGNC’s portfolio investments are guaranteed by the US government. The company’s portfolio includes $70.7 billion in such agency-supported securities, out of a total value of $93 billion.AGNC reported fiscal Q1 earnings at the end of April, and beat the forecast on EPS. Per-share earnings came in at 57 cents, based on $65 million in net interest income. The income interest figure is down significantly from the previous quarter, reflecting the economic troubles caused by the COVID-19 pandemic. On a positive note, AGNC’s cash holdings increased 55% in the first quarter, reaching $1.29 billion by March 31.A solid cash position and safe guarantees on the portfolio make AGNC an attractive investment, and the reliable monthly dividend adds icing to that cake. Like EFC above, AGNC lowered its monthly payment in Q1. The new payment is 12 cents per share per month, which annualized to $1.44 and gives a strong yield of 11.5%. At 63.2%, the payout ratio shows that the dividend is easily sustainable at current income levels – and has room to raised back to previous rates when conditions warrant.Diana is bullish on this stock and upgrades his rating from Hold to Buy. The analyst noted, "While turmoil in the mortgage markets at the end of March resulted in losses and lower book values for all mREITs, AGNC was able to meet all of its margin calls and, importantly, take relatively fewer realized losses, and therefore retain more earnings power post-turmoil. This is why we believe the dividend, currently yielding 11.7% (vs. ~5% for peers) is safe."Along with the Buy rating, Diana gives AGNC a $15 price target, indicating a potential for 20% upside appreciation in the coming 12 months.The analysts are somewhat cautious on AGNC, a sentiment caught by the 8 to 3 split between Buy and Hold reviews. The consensus rating on the stock remains a Moderate Buy, while the $14.53 average price target implies a 14% upside potential. (See AGNC stock analysis on TipRanks)Manhattan Bridge Capital (LOAN)Last on our list is a NYC-based micro-cap lending company, Manhattan Bridge Capital. The company offers short-term financing and collateralized loans. Typical collateral includes real estate and tradeable stock, and the loans are usually used as first mortgages. LOAN originates, services, and manages its loan portfolio, and most of its customers are professional real estate investors and developers.The coronavirus epidemic has hurt real estate development and construction – exactly the type of projects that LOAN finances – in general, but that hit has been especially hard in New York City. At both the State and City levels, lockdown restrictions have been severe, and the mortgage loan environment is described by Diana as ‘challenging.’On a positive note, LOAN has covered its quarterly dividend payment, despite lower Q1 earnings. At 11 cents per share, the quarterly dividend annualized to 44 cents and offers investors a yield of 10.8%. Again, this compares favorably to most investment return yields out there.The high dividend yield alone makes this an attractive investment opportunity, but Diana also points out the stability of Manhattan Bridge’s portfolio, writing, “LOAN has never had to foreclose on a property and has never experienced a loan default.”With the stable portfolio in mind, Diana goes on to say, “We believe LOAN deserves to trade at a P/E premium to [peers] because of its: 1) lower leverage; 2) higher profitability; 3) better credit quality; 4) lower earnings volatility; and 5) dividend growth (which is possible in 2021, in our view, if the environment improves and stabilizes).”Diana’s $6 price target on the stock implies a healthy 46% one-year upside potential, and fully backs his Buy rating on the stock. Diana’s is the only recent Wall Street review of this stock – but should his thesis prove correct, expect LOAN to attract both stock analysts and investors in the near future. It offers a low cost of entry with a high potential return – an unbeatable combination. (See LOAN stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

General Electric (GE) shares have been on the decline as of late. As a result, many investors have been understandably worried. Such sentiments have placed the American manufacturing giant on the market spotlight, and begs the question: is it still worth investing in at current levels? Traversing turbulent market conditions, the outlook seems bleak for the 128-year-old conglomerate. Is there no way up for the aviation unit of General Electric? What about its other subsidiaries? Investor James Richman bets GE is likely to touch down $5-level. From there, the tech investor is bullish that the price will double in value and hit $10 again.Source: Flickr GE: a legacy of over 120 yearsAmid the impact of coronavirus specifically in both travel and hospitality industries, GE's esteemed aviation unit has been feeling the most pressure. The demand for airplanes has shrunk tremendously forcing the company's management to schedule a 25% workforce reduction globally. This is in consonance to the 10% layoff in its US workforce which was announced in March. These difficult cost-cutting measures are deemed necessary by David Joyce, CEO of the GE Aviation Unit that employs a workforce of around 52,000 people.Significant drops since coronavirusGE Aviation supplies jet engines to giant aircraft makers like Airbus and Boeing. The projection of Boeing, a 10% workforce drop amidst its $641m loss, certainly adds up to GE's current woes.  Investor betting on the company bouncing backHowever, one investor who is known to take a different outlook is Latvian-born investor James Richman. With investments in both public and private companies, and his most notable investments including tech giants such as Uber, Tesla, and Facebook, his approach is understood to be contrarian. Yahoo! Finance reports he is taking the opposite approach when compared to Warren Buffet as Richman bets GE's price to temporarily touch upon $5-level. From that level, it is projected to climb its way back to $10, making the 100% rally. The Monaco-based investor has also made headlines when he reportedly pledged $18m in the fight against coronavirus as he mobilizes his biomedical investments in the said efforts. Richman has been historically known to take the contrarian approach in investing. With investments that seemed unorthodox at one point, he has earned respect in the finance field because of his firm's outstanding performance during the 2008 financial crisis. Not open to the general public and mainly dealing with ultra high net worth individuals (UHNWI) and institutional investors, his clients have reported impressive annual earnings for over a decade.Comparison to the last financial crisisIt is not the first time GE had felt the backlash of market recessions. In 2008, the company's shares dropped by 78% tracing the period of the global recession. In 2 years, GE's shares dropped from $27 to $6. The broader S&P also fell that time, but with a conservative 51%.Still worth buying at current levels?GE recovered from the 2008 recession with tremendous momentum. After being bailed out by the federal government to the tune of $139 billion, it experienced an 82% uptick between March 2009 and January 2010. This is more than the 48% bounce back the S&P managed over the same period. Generally, the performance of its stock will still hinge on the developments in the handling of coronavirus pandemic, considering that the aviation division of the company is being hammered as a result. Efforts of which have been showing positive signs of recovery. Meanwhile, the demand for healthcare, government interventions, and the continuous development of treatments and vaccines is seen to help push the shares towards upwards direction in the long run: provided that its wings can weather the storm like it did in 2008.  More recent articles from Smarter Analyst: * RBC: 2 Strong Value Stocks to Buy Now * Look Beyond 2Q, General Motors Will Outperform the Sector, Says Analyst * Coronavirus Vaccine Could Add Massive Value to This Small-Cap Stock, Says Analyst * Can Seanergy Maritime Stock Add 150% Over the Next Year? This Analyst Says 'Yes'

GitHub on Wednesday announced two new security features designed to help developers identify vulnerabilities and potential secrets in their code.

The company announced several new products at its Satellite virtual conference, including ones aimed at helping customers write and consume more secure code.

read more

A large-scale attack campaign has targeted over 900,000 WordPress websites through vulnerabilities in plugins and themes, WordPress security company Defiant revealed this week.

read more

The Czech Republic and the United States have signed a joint declaration Wednesday for cooperating on security of 5G technology.

read more

Researchers have found another vulnerability in software made by Schneider Electric that is similar to the one exploited by the notorious Stuxnet malware.

read more

Popular communications platform provider Zoom Video announced on Thursday that it has acquired secure messaging and file-sharing service Keybase for an undisclosed sum. The move is the latest by the company as it attempts to bolster the security of its offerings and build in end-to-end encryption that can scale to the company’s massive user base.

read more

Naikon, a Chinese APT group that disappeared after its activities were disclosed in 2015, has been rediscovered and may have remained active but unrecognized since the 2015 reports. Researchers have uncovered evidence of a five-year stealth campaign against similar targets in the same geographical area that they believe to be conducted by Naikon.

read more

Recorded Future this week announced the availability of Express, a free web browser extension designed to help security teams prioritize vulnerability patching and alerts from security information and event management (SIEM) tools.

read more

North Korea-linked hacking group Lazarus has been leveraging a Mac variant of the Dacls Remote Access Trojan (RAT), Malwarebytes reports.

read more

A couple of Salt vulnerabilities addressed last week were abused over the weekend to hack Algolia’s infrastructure, the search-as-a-service startup revealed.

read more

Cisco’s Talos threat intelligence and research group revealed on Wednesday that one of its researchers discovered a critical remote code execution vulnerability in the CODESYS Control SoftPLC industrial controller software.

read more

Thinking of Your OT Network as an Extension of Your IT Network Will Give You a Consolidated Picture of Your Technology Infrastructure

read more

Cisco Patches High Severity Vulnerabilities in Adaptive Security Appliance (ASA) and Firepower Threat Defense (FTD)

Cisco this week released security updates to address more than 30 vulnerabilities in various products, including 12 high severity flaws impacting Adaptive Security Appliance (ASA) and Firepower Threat Defense (FTD).

read more

Samsung this week released its May 2020 set of security updates for Android smartphones, which includes a patch for a critical vulnerability impacting all of its devices since 2014. 

read more

New York state's top prosecutor on Thursday announced that the company Zoom would improve security measures, after flaws were detected as the video conferencing platform soared in popularity amid the coronavirus pandemic.

read more

Microsoft says it’s investigating claims that its GitHub account has been hacked, and while some say the leaked files appear to be legitimate, it’s unlikely that they contain any sensitive information.

read more

Threat actors are actively targeting a vulnerability in the Elementor Pro plugin for WordPress to compromise websites, WordPress security company Defiant warned this week.

read more

More than 30 technology and telecom companies announced this week that they have formed a new alliance, the Open RAN Policy Coalition, that calls for open and interoperable 5G systems.

read more